On 29 September 2026 the FDA recorded a supplement to an abbreviated new drug application for rifampicin held by Fresenius Kabi USA. Supplements to generic applications usually cover manufacturing, labelling or packaging changes. The FDA database entry does not describe the change, and no safety communication accompanied it.
Nothing here alters prescribing. It is worth knowing only for teams that use this supplier's product, who may see updated labelling or packaging. Rifampicin's familiar cautions remain the clinically important ones: its strong enzyme induction, hepatotoxicity in combination regimens, and orange discoloration of body fluids.
- No change to rifampicin prescribing follows from this supplement.
- Check for updated package inserts if your hospital stocks this supplier's rifampicin.
- Review every patient's medicines for interactions before starting rifampicin; it lowers levels of many drugs.
- Warn patients that urine, sweat and tears will turn orange and that soft contact lenses may stain.
Why it matters
Regulatory activity on an old drug is usually paperwork, and reading it that way avoids needless alarm.
Don't overread it
A licence supplement is not a new indication or a safety warning.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free